This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
BIO-Europe 2018

Microbiome Drug Development: An Investigation Into Challenges And Innovative Pipeline Approaches

Posted by on 15 October 2018
Share this article

The discovery and deep investigation of the microbiome has been one of the most cutting-edge advances in biomedical research of recent times, but as the science moves forward new hurdles are emerging for microbiome therapies. Download the full whitepaper to learn more about developments in microbiome.

DOWNLOAD-WHITEPAPER-ngt

• Research is now very much focused upon investigating
how exactly the microbiome’s interactions within the body contribute to health and disease.

• As a deeper understanding of these interactions is gained, the floodgates have opened for drug development companies to investigate the potential of microbiome therapies for the treatment of disease.

• So what? With the microbiome being a new area of research, it brings new challenges. Specifically, development of technology to allow for effective delivery of these new therapeutics to the microbiome is an obstacle R&D teams must face.

Every human being hosts between 10 trillion and 100 trillion symbiotic micro-organisms, including bacteria, viruses and archaea. The collective genomes of these micro-organisms form what is known as the human microbiome. As research reveals more about the microbiome, the pharmaceutical industry can better understand how it may interact with different types of drug in the body, which in turn may affect the way the sector goes about developing drugs in the future.

bio-europe-copenhagen

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down